CVS — Q2 2026 Financial Report Analysis

Profit nearly doubled, but half of it is the absence of last year's charges

CVS Health's second quarter of 2026 (the three months ended June 30, 2026) looks dramatic at the top: operating income of $4.70 billion, up 97.5% from $2.38 billion, on revenue up 7.3% to $106.1 billion. Generally Accepted Accounting Principles (GAAP) diluted earnings per share — the official, unadjusted profit figure divided across all shares — came in at $2.31 versus $0.80, close to a tripling.

That comparison is not a clean one. The June 2025 quarter carried $833 million of legacy litigation charges tied to two court decisions on past business practices, plus a $471 million premium deficiency reserve (an accounting charge a health insurer takes when it expects a block of policies to lose money for the rest of the contract period) in the Group Medicare Advantage line. Together that is $1.30 billion of prior-year costs that simply did not repeat — roughly 56% of the $2.32 billion increase in operating income, by our calculation from the figures the filing discloses. The cleaner number is adjusted EPS, which strips out the litigation and similar items: $2.58 against $1.81, up 42.5%. Still a large improvement, and the reason management raised full-year guidance twice over on three separate measures.

The quarter in numbers

Operating margin — the share of revenue left after the costs of running the business, before interest and tax — is the number that shows how thin this business is. Even after doubling profit, CVS keeps about four and a half cents of each revenue dollar at the operating line. On $106 billion of quarterly revenue, small changes in medical costs move earnings a long way.

Health Care Benefits: the medical benefit ratio did the work

The insurance arm (Aetna) is where the real recovery sits. Revenue rose only 3.5% to $37.5 billion, but operating income more than doubled to $2.19 billion from $1.00 billion, and adjusted operating income rose 85.5% to $2.43 billion.

The driver is the medical benefit ratio: health care costs as a percentage of premium revenue, or how much of every premium dollar goes straight back out as medical claims. It fell to 87.4% from 89.9% — 250 basis points, meaning CVS kept an extra 2.5 cents of each premium dollar. The filing attributes this to "improved underlying performance in the Government business and the absence of a $471 million premium deficiency reserve recorded within the Group Medicare Advantage product line in the prior year."

Split the $1,118 million adjusted operating income increase: about $471 million is the reserve that did not repeat, leaving roughly $647 million — still close to a 50% underlying gain — from actual improvement in Medicare pricing and cost control. That is the margin recovery plan working, not just an easy comparison.

Two things complicate the picture. First, the revenue mix has shifted hard: Government premiums (Medicare and Medicaid) rose 9.9% to $28.5 billion while Commercial premiums fell 19.7% to $6.6 billion, largely because CVS exited the individual exchange business in 2026. Membership is down about 700,000 year over year to 26.0 million and was flat against March 31, 2026. The margin is improving on a deliberately smaller, more Government-weighted book — CVS is repricing and shedding business rather than growing into the recovery. Second, on the six-month view the filing notes the MBR improvement was "partially offset by lower favorable prior period development" — meaning last year's claims reserves are proving less over-stated than they used to, a tailwind that is fading.

Health Services and Pharmacy: strong GAAP, single-digit underlying

Both of the other segments show the same gap between headline and substance, and in both cases it is the same $833 million of prior-year litigation charges.

Health Services (the pharmacy benefit manager) grew revenue 11.5% to $51.8 billion, driven by "pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements" — that is, more expensive branded drugs flowing through, not more volume. Pharmacy claims processed were flat on a 30-day equivalent basis. GAAP operating income rose 45.5% to $1.60 billion, but operating expenses fell $236 million mainly on "the absence of a $291 million legacy litigation charge." Adjusted operating income rose $158 million, or 10.0%.

Pharmacy & Consumer Wellness (the retail stores) is the sharpest example: revenue up just 0.7% to $33.8 billion, yet GAAP operating income up 91.7% to $1.41 billion. Operating expenses fell $168 million "primarily due to the absence of a $542 million legacy litigation charge recorded in the prior year." Adjusted operating income rose $137 million, or 10.2%.

Inside that near-flat retail revenue line are two forces close to cancelling out. Prescriptions filled rose 4.3% and pharmacy same-store prescription volume rose 7.0%, helped by the Rite Aid prescription file acquisitions completed in Q3 2025 — but the Omnicare long-term-care pharmacies were deconsolidated in September 2025 and their volume is gone from the comparison. On price, drug mix and brand inflation were "largely offset by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure." So 7.0% more scripts through the same stores converted to only 2.9% same-store sales growth, and front-store sales grew 1.0%. CVS is dispensing meaningfully more and being paid barely more for it.

Note also the comp distortion: pharmacy same-store sales grew 18.1% in the year-ago quarter. This year's 2.9% is against a base that was already inflated.

The tax line is quietly worth 30 cents

Pre-tax income rose to $3.98 billion from $1.65 billion, but the tax provision rose only to $982 million from $634 million. That is an effective tax rate of about 24.7% this quarter against roughly 38.5% a year ago — the prior-year rate was pushed up because the litigation charges were largely not deductible. Had this quarter been taxed at last year's rate, net income would have been roughly $600 million lower. Anyone reading the 189% GAAP EPS growth as operating improvement is reading a tax-rate normalization as well.

Cash and guidance

Year-to-date cash from operations was $10.6 billion, up $4.1 billion, on "the timing of payments and receipts and improved operating performance in the Health Care Benefits segment." For the first half, revenue was $206.5 billion (+6.7%), operating income $9.38 billion (+63.0%) and diluted EPS $4.61 against $2.21.

Management raised all three headline guidance measures for full-year 2026:

• GAAP diluted EPS to $6.84–$7.04, from $6.24–$6.44
• Adjusted EPS to $7.90–$8.10, from $7.30–$7.50
• Cash flow from operations to at least $11.5 billion, from at least $9.5 billion

The company says the increase reflects the Health Care Benefits and Pharmacy & Consumer Wellness segments, "while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds."

That caution is visible in the arithmetic. Adjusted EPS for the first six months was $5.16 (against $4.06 a year ago). Subtract that from the new full-year range and the implied second half is $2.74 to $2.94 — barely half the first-half figure, against $2.58 in this quarter alone. The GAAP guide implies the same shape: $6.84–$7.04 for the year less $4.61 booked in the first half leaves $2.23–$2.43. Some of that is ordinary seasonality — a health insurer's medical costs climb through the year as members meet deductibles, so the MBR is structurally higher in the second half — but the gap is wide enough that management is also holding back room against the "elevated cost trends" it names. The $2.0 billion increase in the operating cash flow guide is likewise larger than the EPS raise alone would imply, and the filing attributes part of the year-to-date cash figure to timing of payments and receipts, which is working capital rather than earnings.

Takeaway: The durable news is the Aetna medical benefit ratio at 87.4%, down 250 basis points, with roughly $647 million of the $1.1 billion adjusted profit gain coming from genuine Government-business improvement rather than last year's non-repeating reserve. Everything else — the doubled operating income, the tripled GAAP EPS — is substantially the absence of $833 million in litigation charges and a tax rate that returned to normal.

What to watch

The insurance recovery is real but is being achieved on a shrinking membership base, with the individual exchange exit removing revenue and favorable prior-period reserve development fading. The question for the next two quarters is whether the MBR holds once those two supports are gone and the easy year-over-year comparisons end — from Q3 2026 the litigation charges drop out of the base and growth has to come from operations.

The retail pharmacy business is the more uncomfortable one: 7.0% same-store script growth producing 2.9% same-store sales, with reimbursement pressure and regulatory price cuts absorbing the volume. Adjusted profit there grew 10.2%, largely on Rite Aid file acquisitions that will annualize out of the comparison after Q3 2026. Our read is that Aetna's margin repair carries the story through the rest of 2026 and the guidance raise is credible, but the second-half guide implies management expects the pace to slow, and on a 4.4% operating margin there is very little cushion if medical cost trend turns.